The Biotechnology Innovation Organization (BIO) has released a new report, “Emerging Therapeutic Company Investment and Deal Trends,” highlighting 10 years (2006-2015) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers clinical pipeline snapshots to provide context on the degree of industry partnering and the contribution of emerging companies.
“Investment and licensing are the lifeblood of today’s emerging biotechnology companies searching for cures and treatments for patients suffering from devastating and life-threatening diseases,” said Cartier Esham, Ph.D., BIO’s executive vice president, Emerging Companies. “This data will deepen our understanding of investor behavior and deal making trends, a critical consideration for those seeking to encourage medical innovation and unleash the full potential for biotechnology for patients in need of new treatment options.”
Some of the key findings include:
“Overall, this report shows that the state-of-the-industry has been strong in recent years and we expect to hear about recent success stories at next month’s BIO International Convention in San Francisco,” said Dr. Esham. “With 2016 bringing its own set of challenges, we are confident that partnerships formed at the Convention this year will play a critical role in ensuring that emerging companies have the capital and strategic relationships necessary to develop the next generation of groundbreaking medical innovation.”
The free report can be accessed here. The Thomson Reuters Cortellis Venture Intelligence and ReCap products, Informa’s Strategic Transactions and Biomedtracker Databases, BioCentury’s BCIQ, and EvaluatePharma were resources for this endeavor.